These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 16679946)
61. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Sofroniadou K; Drossou M; Foundoulaki L; Konstantopoulos K; Kyriakoy D; Zervas J Drug Saf; 1990; 5(2):152-4. PubMed ID: 2322425 [TBL] [Abstract][Full Text] [Related]
62. THE VALUE OF DESFERRIOXAMINE AS A DIAGNOSTIC TEST IN IRON OVERLOAD. PAWELSKI S; TOPOLSKA P; ROSZKOWSKI S; RADECKA K Pol Med Sci Hist Bull; 1965 Apr; 8():69-71. PubMed ID: 14319221 [No Abstract] [Full Text] [Related]
63. Acute kidney injury due to deferoxamine in a renal transplant patient. Hirschberg R; Bennett W; Scheinman J; Coppo R; Ponticelli C Nephrol Dial Transplant; 2008 Aug; 23(8):2704-5; author reply 2705. PubMed ID: 18515307 [No Abstract] [Full Text] [Related]
65. Aeromonas hydrophila sepsis with septic embolism and rhabdomyolysis in a chronic iron overload haemodialysis patient treated with deferoxamine. Chompoonuch S; Wangsomboonsiri W; Wongprasit P; Sungkanuparph S; Phakdeekitcharoen B NDT Plus; 2009 Aug; 2(4):303-5. PubMed ID: 25984022 [TBL] [Abstract][Full Text] [Related]
66. Deferoxamine as a potential cause of incidentally found T1-hyperintense urine on magnetic resonance imaging. Winters T; White CM Radiol Case Rep; 2022 Jan; 17(1):111-114. PubMed ID: 34777674 [TBL] [Abstract][Full Text] [Related]
67. Re: "Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats," and "Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model". Mazaheri S; Moaeidi BA; Nematbakhsh M Int J Prev Med; 2014 Jun; 5(6):800-1. PubMed ID: 25013703 [No Abstract] [Full Text] [Related]
68. Iron overdose in a fifteen-month-old child. Judkins D J Emerg Nurs; 1984; 10(1):31-3. PubMed ID: 6366313 [No Abstract] [Full Text] [Related]
71. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690 [TBL] [Abstract][Full Text] [Related]
72. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Wali YA; Taqi A; Deghaidi A Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089 [TBL] [Abstract][Full Text] [Related]
73. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Lombardo T; Ferro G; Frontini V; Percolla S Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945 [TBL] [Abstract][Full Text] [Related]
74. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575 [TBL] [Abstract][Full Text] [Related]
75. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload. Nelson SC; Hennessy JM; McDonough EA; Guck KL J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946 [TBL] [Abstract][Full Text] [Related]